A Multi-Center, Randomized, Double Blind, Placebo Controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.

Trial Profile

A Multi-Center, Randomized, Double Blind, Placebo Controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Schwarz Pharma AG; UCB
  • Most Recent Events

    • 20 Feb 2009 Primary endpoint 'Headache frequency' has not been met.
    • 26 Jul 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov
    • 15 Feb 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top